Sign In
Buy BOLD
$1.40
-0.0300 (-2.10%)
At Close: Jun 22, 2026
BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders
11:55am, Tuesday, 23'rd Jun 2026
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Boundless Bio, Inc. (NASDAQ: BOLD) and Serapha Bio, Inc. Upon closing of the proposed transacti
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
07:30am, Tuesday, 23'rd Jun 2026
Combined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
07:00am, Friday, 08'th May 2026
Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
04:49pm, Friday, 17'th Apr 2026
Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers Findin
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
09:17am, Wednesday, 01'st Apr 2026
TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exo
Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader
03:25am, Friday, 20'th Mar 2026
Boundless Bio offers a highly asymmetric risk/reward profile, trading at a $25M valuation with $107.6M in cash and a runway into 2H 2028. BBI-940, BOLD's first direct ecDNA-targeting asset, is enterin
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to
NurExone Announces Corporate Updates
08:28am, Wednesday, 11'th Mar 2026
Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement Closing Consulting Agreement with Former Bayer Principal Scientist, BOLD Award
DOT'S® INTRODUCES DOT'S ORIGINAL SNACK MIX - A BOLD NEW TAKE ON SNACKING
09:00am, Tuesday, 10'th Mar 2026
Dot's brings its iconic buttery-rich pretzels and bold Original seasoning to Snack Mix! HERSHEY, Pa.
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
07:00am, Monday, 09'th Mar 2026
KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1
Boundless Bio to Participate in the Leerink Global Healthcare Conference
07:00am, Wednesday, 04'th Mar 2026
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why
01:01pm, Friday, 13'th Feb 2026
Boundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
07:00am, Thursday, 05'th Feb 2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to p
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
07:00am, Tuesday, 20'th Jan 2026
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runwa
BUBBA® UNVEILS A BOLD, NEW BRAND IDENTITY AND NEXT-GEN WATER BOTTLE DESIGNS, TURNING EVERYDAY HYDRATION INTO PERSONAL EXPRESSION
07:00am, Wednesday, 14'th Jan 2026
It's Not About the Water, It's About the Drip. bubba®'s New Look, Fashion-forward Finishes, And Bold Colorways, Transform Hydration into a Statement Piece ATLANTA, Jan. 14, 2026 /PRNewswire/ -- Tod
